Novavax, Inc.
Novavax, Inc. (NVAX) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · NVAX · as of Sep 30, 2025
Ownership Breakdown
286
Institutional Holders
▼ 9 vs Q2
$894.70M
Total Inst. Value
▲ $251.77M vs Q2
164.44M
Shares Outstanding
freeFloat 86.03%
103.21M
13F Shares Held
▲ 1.07M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
NVAX largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
VANGUARD GROUP INC biological products, (no diagnostic substances) | 15.19M | 9.38% | 9.38% | $131.74B | Nov 7, 2025 | ▼ 238.6K |
BLACKROCK, INC. biological products, (no diagnostic substances) | 12.77M | 7.88% | 7.88% | $110.74B | Nov 12, 2025 | ▲ 29.9K |
SHAH CAPITAL MANAGEMENT biological products, (no diagnostic substances) | 11.81M | 7.29% | 7.29% | $102.41B | Nov 12, 2025 | ▲ 300.0K |
STATE STREET CORP biological products, (no diagnostic substances) | 7.20M | 4.44% | 4.44% | $62.40B | Nov 14, 2025 | ▲ 372.5K |
SANOFI biological products, (no diagnostic substances) | 6.88M | 4.25% | 4.25% | $59.65B | Nov 4, 2025 | — held |
D. E. SHAW & CO., INC. biological products, (no diagnostic substances) | 4.27M | 2.64% | 2.64% | $37.06B | Nov 14, 2025 | ▲ 333.1K |
COATUE MANAGEMENT LLC biological products, (no diagnostic substances) | 3.84M | 2.37% | 2.37% | $33.27B | Nov 14, 2025 | — held |
GEODE CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 3.79M | 2.34% | 2.34% | $32.88B | Nov 12, 2025 | ▲ 23.7K |
UBS GROUP AG biological products, (no diagnostic substances) | 3.52M | 2.17% | 2.17% | $30.49B | Nov 13, 2025 | ▲ 1.26M |
BANK OF AMERICA CORP /DE/ biological products, (no diagnostic substances) | 3.10M | 1.91% | 1.91% | $26.89B | Feb 3, 2026 | ▼ 34.3K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
27
Increased
+8.32M shares1
New Positions
first time holders17
Decreased
−2.54M shares0
Sold Out
fully exitedNet shares change (top 50)
+5.78M
+8.32M / −2.54M
Net new holders
+11
1 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
NVAX insider trading · insider activity
Source: SEC Form 4
2
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Walker Robert Edward EVP, R&D | Apr 14, 2026 | Award | 99,500 | $8.46 | $841.8K | 99.5K | Form 4 ↗ |
Walker Robert Edward EVP, R&D | Apr 14, 2026 | Award | 66,000 | — | — | 6.6K | Form 4 ↗ |
Kelly James Patrick EVP, CFO and Treasurer | Mar 7, 2026 | Tax Withhold | 5,904 | $9.98 | $58.9K | 130.6K | Form 4 ↗ |
Kelly James Patrick EVP, CFO and Treasurer | Mar 2, 2026 | Award | 194,000 | $10.11 | $1.96M | 194.0K | Form 4 ↗ |
Draghia-Akli Ruxandra EVP, Research & Development | Mar 2, 2026 | Award | 139,500 | $10.11 | $1.41M | 139.5K | Form 4 ↗ |
Casey Mark J EVP, Chief Legal Officer | Mar 2, 2026 | Award | 152,000 | $10.11 | $1.54M | 152.0K | Form 4 ↗ |
Jacobs John C President and CEO | Mar 2, 2026 | Award | 551,500 | $10.11 | $5.58M | 551.5K | Form 4 ↗ |
O'Hara Elaine EVP, Chief Strategy Officer | Mar 2, 2026 | Award | 177,500 | $10.11 | $1.79M | 177.5K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Novavax, Inc. (NVAX) is primarily owned by institutional investors, who hold approximately 62.8% of total shares outstanding. Company insiders own approximately 13.97%, while retail and public investors account for the remaining 23.26%.
The largest institutional shareholder of Novavax, Inc. is VANGUARD GROUP INC, holding approximately 15.19 million shares — equal to 9.38% of outstanding shares — as of September 30, 2025.
A total of 286 institutional investors currently hold NVAX stock, with a combined institutional value of approximately $894,704,843 as of the most recent 13F filing period.
Frequently asked questions
NVAX ownershipNovavax, Inc. (NVAX) is primarily owned by institutional investors, who hold approximately 62.8% of shares. The largest shareholder is VANGUARD GROUP INC with a 9.38% stake. Company insiders hold 13.97%. Data sourced from SEC Form 13F as of September 30, 2025.